Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO.
Equillium provided the following description of their company for its IPO: ” We are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas incluEQ.” EQ.” ding transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. “.
Equillium was founded in 2017 and has 7 employees. The company is located at 2223 Avenida de la Playa, Suite 108, La Jolla, CA 92037, US and can be reached via phone at 858-412-5302 or on the web at http://www.equilliumbio.com.
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.